TX-MARY-KAY
As one of the world’s leading skincare innovators in the direct selling and cosmetic industries, Mary Kay continued its decades-long commitment to skin science research by revealing the results of a study to improve skin barrier function and facial redness at the Annual Meeting of the Dermatology Committee organized by the Chinese Association of Integrative Medicine. Mary Kay was also a sponsor of the event, which took place August 8-11 in Lanzhou, Gansu Province, China.
“Mary Kay scientists spend years doing skin research to develop solutions for real people, and real needs,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc. “Part of our commitment is to take an active role in the beauty and scientific communities through our participation in global dermatological conferences, where we can share and learn from other scientific experts to help us develop more effective and innovative products.”
Mary Kay China’s Sr. Manager for Medical Affairs, Dr. Jenny Jiang, shared research results of strategies to improve the skin barrier function and facial redness. These findings may provide important insights to understanding sensitive skin. Attendees included the country’s top dermatologists and esteemed executives from cosmetic companies.
Mary Kay’s Research and Development team is comprised of distinguished scientists who hold doctorates and other advanced degrees across multiple disciplines: skin biology, cell biology, chemistry, biochemistry and more. The team is dedicated to conducting ongoing breakthrough research and sharing impactful findings related to skin health with the scientific and beauty communities at large.
Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality, and performance. Mary Kay holds more than 1,500 patents for products, technologies, and packaging designs in its global portfolio. Last year, the company opened a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, provide irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics, fragrances and nutritional supplements. Through The Mary Kay FoundationSM , the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190809005304/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 11:15:00 CET | Press release
Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in Wellington, Palm Beach County, FloridaStrengthens Modon’s global presence and enables knowledge exchange across large-scale mixed-use, hospitality and lifestyle developments Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championshi
Epassi Announces Leadership Transition26.11.2025 11:00:00 CET | Press release
Nickyl Raithatha to join as Group CEOPekka Rantala to remain on Board as Non-Executive Chair Epassi Group, a European leader in digital employee benefits technology, today announced that Nickyl Raithatha will join as Chief Executive Officer. Nickyl will assume the role in 2026. Pekka Rantala, who has served as CEO since September 2019, will remain on the Board as Non-Executive Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126015983/en/ Pekka Rantala and Nickyl Raithatha Over the past six years, Epassi Group has evolved from a Nordic success story into one of Europe’s leading SaaS employee benefits and wellbeing platforms. The company has expanded both its geographic footprint as well as its product portfolio, driven by a powerful combination of strong organic growth and strategic acquisitions, with backing from TA Associates and Warburg Pincus. Today it has a presence in ten countries and a team of 1,000 people. W
Enerin raises €15 million Series A to industrialise modular high-temperature heat pumps for global industry26.11.2025 10:00:00 CET | Press release
Norway-based technology leader in industrial heat pumps, Enerin AS, has raised €15 million in an oversubscribed Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy. The investment marks Enerin’s transition from technology pioneer to serial production. Proceeds will expand commercial and manufacturing operations, and accelerate next-generation development. Johnson Controls’ participation provides strategic validation and global reach from one of the world’s leading providers of energy systems. Enerin, a technology leader in high-temperature heat pumps, has raised €15 million (NOK 180 million) in a Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy, with participation from PSV Hafnium and Momentum. “This investment marks our shift from pioneering to full industrialisation, bringing proven high-temperature technology from Norway to industries worldwide,” said Arne Høeg, Founder and CEO of Enerin. “Industrial companie
IQM to Invest Over €40 Million to Expand Finland Production Facility, Accelerate Innovation and Fuel Growth26.11.2025 09:49:00 CET | Press release
The new facility will produce advanced quantum chips for error corrected quantum computers, almost double the cleanroom space and system assembly line capacity to produce up to 30 quantum computers per year. The integrated quantum computer production line will be one of the world’s most advanced of its kind combining fabrication of quantum chips and system assembly. The expansion is expected to be completed by the first quarter of 2026. The expansion is part of IQM’s long-term commitment to scale its infrastructure and execute the ambitious technology roadmap aiming at 1M quantum computers by 2033. IQM Quantum Computers, a global leader in superconducting quantum computers, today announced over €40 million investment to expand its state-of-the-art production facility in Finland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126943986/en/ This strategic expansion will accelerate the development, fabrication and testing of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom